drugset / Trial / NCT04937153
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with pembrolizumab in Japanese study participants with malignant solid tumors.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2024-10-01
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acasunlimab | Monoclonal antibody | 15 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |